Greenwood Capital Associates’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-16,067
| Closed | -$660K | – | 208 |
|
|
2022
Q1 | $660K | Buy |
16,067
+554
| +4% | +$22.8K | 0.17% | 106 |
|
|
2021
Q4 | $674K | Buy |
15,513
+103
| +0.7% | +$4.48K | 0.1% | 167 |
|
|
2021
Q3 | $772K | Sell |
15,410
-392
| -2% | -$19.6K | 0.12% | 137 |
|
|
2021
Q2 | $995K | Buy |
15,802
+70
| +0.4% | +$4.41K | 0.15% | 114 |
|
|
2021
Q1 | $1.46M | Buy |
15,732
+1,092
| +7% | +$101K | 0.23% | 83 |
|
|
2020
Q4 | $1.31M | Buy |
14,640
+2,939
| +25% | +$263K | 0.22% | 84 |
|
|
2020
Q3 | $1.21M | Buy |
11,701
+43
| +0.4% | +$4.44K | 0.23% | 78 |
|
|
2020
Q2 | $922K | Buy |
11,658
+2,103
| +22% | +$166K | 0.21% | 75 |
|
|
2020
Q1 | $553K | Sell |
9,555
-603
| -6% | -$34.9K | 0.16% | 74 |
|
|
2019
Q4 | $548K | Buy |
10,158
+1,750
| +21% | +$94.4K | 0.12% | 102 |
|
|
2019
Q3 | $440K | Buy |
8,408
+671
| +9% | +$35.1K | 0.11% | 99 |
|
|
2019
Q2 | $374K | Buy |
7,737
+291
| +4% | +$14.1K | 0.09% | 118 |
|
|
2019
Q1 | $376K | Buy |
7,446
+1,125
| +18% | +$56.8K | 0.1% | 109 |
|
|
2018
Q4 | $375K | Buy |
6,321
+742
| +13% | +$44K | 0.1% | 115 |
|
|
2018
Q3 | $367K | Buy |
5,579
+26
| +0.5% | +$1.71K | 0.08% | 132 |
|
|
2018
Q2 | $280K | Buy |
5,553
+940
| +20% | +$47.4K | 0.06% | 147 |
|
|
2018
Q1 | $243K | Sell |
4,613
-246
| -5% | -$13K | 0.06% | 165 |
|
|
2017
Q4 | $226K | Buy |
+4,859
| New | +$226K | 0.05% | 184 |
|